QGEN
QIAGEN NV
NYSE · Healthcare · Medical - Diagnostics & Research · NL
$41.88
−1.46%Price chart
Aug 13Aug 18Aug 21Aug 26Aug 31Sep 3Sep 9Sep 14
ValuationView details →
P/E (Fwd)
16.8x
EV/EBITDA
12.9x
Market Cap
$8.65B
MomentumView details →
1D Return
−1.46%
YTD Return
−10.69%
RSI (14)
47.0
ValuationView details →
P/E (Fwd)
16.8x
EV/EBITDA
12.9x
Market Cap
$8.65B
RSI (14)
47.0
MomentumView details →
1D Return
−1.46%
YTD Return
−10.69%
SummaryUpdated Jun 1, 2026
QIAGEN N.V. (NASDAQ:QGEN) is a Netherlands-based multinational biotechnology company founded in 1986 that specializes in molecular diagnostics and life sciences research technologies. Originally established as a spin-off from the University of Düsseldorf, QIAGEN went public in 1996 and has grown through both organic expansion and strategic acquisitions to become a leading provider of sample preparation and molecular testing solutions. The company serves customers across molecular diagnostics, academic research, pharmaceutical development, and applied testing markets worldwide, with operations spanning over 35 countries and headquarters in Venlo, the Netherlands.
Similar companies
Latest newsMore news →
QIAGEN N.V. announced the commercial launch of QIAsymphony Connect, an IVD-compliant platform for automated clinical nucleic acid extraction, building on its QIAsymphony platform with over 3,300 cumulative placements worldwide.19d agoQiagen N.V. announced that Jonathan M. Pratt will become CEO on September 1, 2026, succeeding Thierry Bernard, who will step down but support the transition through the end of the year.22d ago